Fintel reports that on December 1, 2025, Lake Street maintained coverage of TELA Bio (NasdaqGM:TELA) with a Buy recommendation.

Analyst Price Forecast Suggests 327.30% Upside

As of November 17, 2025, the average one-year price target for TELA Bio is $4.74/share. The forecasts range from a low of $1.26 to a high of $7.35. The average price target represents an increase of 327.30% from its latest reported closing price of $1.11 / share.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for TELA Bio is 100MM, an increase of 29.59%. The projected annual non-GAAP EPS is -1.93.

What is the Fund Sentiment?

There are 62 funds or institutions reporting positions in TELA Bio. This is an decrease of 7 owner(s) or 10.14% in the last quarter. Average portfolio weight of all funds dedicated to TELA is 0.27%, an increase of 14.43%. Total shares owned by institutions increased in the last three months by 0.75% to 24,684K shares. The put/call ratio of TELA is 0.03, indicating a bullish outlook.

What are Other Shareholders Doing?

Nantahala Capital Management holds 5,112K shares representing 11.68% ownership of the company. No change in the last quarter.

Essex Woodlands Management holds 4,111K shares representing 9.39% ownership of the company. No change in the last quarter.

Silverarc Capital Management holds 2,783K shares representing 6.36% ownership of the company. In its prior filing, the firm reported owning 2,780K shares , representing an increase of 0.11%. The firm decreased its portfolio allocation in TELA by 43.77% over the last quarter.

Stonepine Capital Management holds 2,156K shares representing 4.92% ownership of the company. In its prior filing, the firm reported owning 2,084K shares , representing an increase of 3.33%. The firm decreased its portfolio allocation in TELA by 34.17% over the last quarter.

DAFNA Capital Management holds 1,441K shares representing 3.29% ownership of the company. No change in the last quarter.